An open trial of naltrexone for opiate dependence

References

• Archer S. Historical perspective on the chemistry and development of naltrexone. Narcotic antagonists: naltrexone pharmacochemistry and sustained release preparations, NIDA Research Monograph, RE Willette, G Barnett. US Department of Health and Human Services, Washington, DC 1981; 28: 132–146, In
   Google Scholar
• Verebey K. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics. Narcotic antagonists: naltrexone pharmacochemistry and sustained release preparations, NIDA Research Monograph, RE Willette, G Barnett. US Department of Health and Human Services, Washington, DC 1981; 147–158, In
   Google Scholar
• Resnick RB, Volavka J, Freedman AM, et al. Studies of EN—1639A (naltrexone): a new narcotic antagonist. Am J Psychiat 1974; 131: 646–650
   PubMed Web of Science ®Google Scholar
• Judson BA, Carney TM, Goldstein A. Naltrexone treatment of heroin addiction: efficacy and safety in a double blind dosage comparison. Drug Alcohol Depend 1981; 7: 325–346
   PubMed Web of Science ®Google Scholar
• Bradford A, Hurley F, Golondzowski O, Dorrier C. Interim report on clinic intake and safety data collected from 17 NIDA funded naltrexone studies. NIDA Res Monogr 1976; 9: 163–171
   Google Scholar
• Pfohol DN, Allen JL, Atkinson RL, Knopman DS, Malcolm RJ, Mitchell JE, Morley JE. Naltrexone hydrochloride (Trexan) a review of serum transaminase elevations at high dosage. NIDA Res Monogr 1986; 67: 66–72
   PubMedGoogle Scholar
• Crowley TJ, Wagner JE, Zerbe G, Macdonald M. Naltrexone induced dysphoria in former opioid addicts. Am J Psychiat 1985; 142: 1081–1084
   PubMed Web of Science ®Google Scholar
• Fram Dlt, Marino J, Holden R. Naltrexone treatment—the problem of patient acceptance. J Subst Abuse Treat 1989; 6: 199–222
   Google Scholar
• Miotto K, McCann MJ, Rawson RA, Frosch D, Ling W. Overdose suicide attempts and death among a cohort of naltrexone 0 treated opioid addicts. Drug Alcohol Depend 1997; 45: 131–134
   PubMed Web of Science ®Google Scholar
• National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Clinical evaluation of naltrexone treatment of opiate dependent individuals. Arch Gen Psychiat 1978; 35: 335–340
   PubMedGoogle Scholar
• Roth A, Hogan I, Farren C. Naltrexone plus group therapy for the treatment of opiate abusing healthcare professionals. J Subst Abuse Treat 1997; 14: 19–22
   PubMed Web of Science ®Google Scholar
• Capone T, Brahen L, Condren R, Kordal N, Melchionda R, Peterson M. Retention and outcome in a narcotic antagonist treatment program. J Clin Psychol 1986; 42: 825–833
   PubMed Web of Science ®Google Scholar
• Osborn E, Grey C, Reznikoff M. Psychosocial adjustment modality choice and outcome in naltrexone versus methadone treatment. Am J Drug Alcohol Abuse 1986; 12: 383–388
   PubMed Web of Science ®Google Scholar
• Ochoa E, Arias F, Somoza JC, Lopez-Ibor JJ. Treatment with naltrexone in opiate dependents: 2 years follow up. Arch Neurobiol (Madrid) 1992; 55: 224–227
   PubMedGoogle Scholar
• Schifano F, Marra R. Naltrexone for heroin addiction: encouraging results from Italy. Int J Clin Pharmacol Ther Toxicol 1990; 28: 144–146
   PubMed Web of Science ®Google Scholar
• Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35: 192–213
   PubMed Web of Science ®Google Scholar
• Lopez-Ibor AJJ, Perez delos Cobos JC, Ochoa E, Hernandes-Herreros M. Maintenance treatment for opiate dependence at a naltrexone clinic. Actas Luso Esp Neurol Psiquatr Cienc Afines 1990; 18: 296–305
   PubMedGoogle Scholar
• Garcia-Alonso F, Gutierrez M, San L, et al. A multicentre study to introduce naltrexone for opiate dependence in Spain. Drug Alcohol Depend 1989; 23: 117–121
   PubMedGoogle Scholar
• San L, Pomarol G, Peri JM, Olle JM, Cami J. Follow up after a six month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addic 1991; 86: 983–990
   PubMedGoogle Scholar
• Lerner A, Sigal M, Bacala A, Shiff R, Burganski I, Gelkopf M. A naltrexone double blind placebo controlled study in Israel. Isr J Psychiat Relat Sci 1992; 29: 36–43
   PubMed Web of Science ®Google Scholar
• Ross R, Horwitz CA, Hager H, et al. Preliminary evaluation of a latex agglutination-inhibition tube test for morphine. Clin Chem 1975; 21: 139–143
   PubMedGoogle Scholar
• Adler FL, Liu CT. Detection of morphine by haemagglutination-inhibition. J Immunol 1971; 106: 1684–1685
   PubMed Web of Science ®Google Scholar
• A treatment outline for approaches to opioid dependence. National Drug Strategy Monograph Series No. 21, RP Mattick, W Hall. Aust Government Publishing Service, Canberra 1993
   Google Scholar